<DOC>
	<DOCNO>NCT00301652</DOCNO>
	<brief_summary>The purpose study access efficacy MMF compare CTX induce remission improve renal function subject ANCA associate vasculitis renal involvement .</brief_summary>
	<brief_title>MMF Versus CTX Induction Treatment ANCA Associated Vasculitis</brief_title>
	<detailed_description>The ANCA-associated vasculitides life threaten . Glucocorticoids cyclophosphamide therapy effective 80 % patient . However , side effect bone marrow suppression , infection , cystitis , infertility , myelodysplasia preclude use cyclophosphamide patient relapse rate high . Recent study show mycophenolic acid ( MPA ) , active metabolite mycophenolate mofetil ( MMF ) , could exhibit multifarious effect endothelial cell , include inhibition ICAM-1 expression , neutrophil attachment , IL-6 secretion , process angiogenesis , contribute efficacy MMF treatment vasculitic lesion lupus nephritis vasculitic lesion . This study feasibility study assess safety effectiveness MMF induce remission subject ANCA-associated SVV compare pulse intravenous cyclophosphamide . After enrollment , subject follow longitudinally , formal measurement disease activity determine use Birmingham Vasculitis Activity Score ( BVAS ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . A new diagnosis ANCA associate vasculitis ( eg . MPA Wegener granulomatous , renal limited vasculitis ) prove histology serology . 2 . Renal involvement attributable active ANCA associate vasculitis least one following : Elevated serum creatinine 150 500 umol/l renal biopsy Demonstrating paucin immune necrotizing glomerulonephritis Red cell cast Haematuria ＞ 30 red blood cells/HPF proteinuria ＞ 1g/24h 3 . Serum ANCA positive indirect immunofluorescence ( IIF ) positivity antiPR3 antiMPO ELISA 4 . Age 18~65 year 1 . More two week treatment cyclophosphamide ( CYC ) cytotoxic drug within previous 6 month oral corticosteroid ( OCS ) 4 week 2 . Coexistence another multisystem autoimmune disease , e.g . SLE 3 . Serum creatinine &gt; 500umol/l 4 . Severe viral infection ( HBV , HCV , CMV ) within 3 month first randomization know HIV infection 5 . Congenial acquire immunodeficiency 6 . Immediately lifethreatening organ manifestation ( e.g . lung haemorrhage dialysis dependence ) 7 . Previous malignancy 8 . Pregnancy inadequate contraception female 9 . AntiGBM antibody positivity 10 . Cerebral infarction due vasculitis 11 . Rapidly progressive optic neuropathy retinal vasculitis orbital pseudotumour 12 . Massive gastrointestinal bleeding 13 . Heart failure due pericarditis myocarditis 14 . Liver dysfunction measure least 2 separate occasion 15 . Age &lt; 18y Age &gt; 65y</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>ANCA</keyword>
	<keyword>vasculitis</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>treatment</keyword>
</DOC>